Our legacy in #RareDisease is rooted in being the first to translate the complex biology of the complement system, an integral part of the immune system, into transformative medicines. Learn about this powerful tool and how it protects the body against harmful invaders in this video.
Alexion Pharmaceuticals, Inc.
Biotechnology Research
Boston, Massachusetts 362,868 followers
Rare inspiration. Changing lives.
About us
Alexion, AstraZeneca Rare Disease was created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. by AstraZeneca. For more than 30 years, Alexion’s mission has been to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines, supportive technologies, and healthcare services. Dedicated to continuing its mission as part of AstraZeneca, Alexion recognizes that patients and caregivers are people first, and by understanding their experiences, Alexion is better able to serve their unique needs. Alexion’s pioneering legacy in rare disease is rooted in being the first to translate the complex biology of the complement system into novel medicines. Alexion pushes boundaries to accelerate discovery of life-changing medicines. Headquartered in Boston, Massachusetts, Alexion has offices around the world and continues to expand its reach to benefit more people globally. GL/NP/0116 GL/NP/0095 Community Guidelines: https://bit.ly/39x9gqy
- Website
-
http://www.alexion.com/
External link for Alexion Pharmaceuticals, Inc.
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Boston, Massachusetts
- Type
- Public Company
- Founded
- 1992
- Specialties
- Biotechnology, Biopharmaceutical, Complement Inhibition, Metabolic Disorders, Neurology, Rare Diseases, Research and Development, hematology, and nephrology
Locations
-
Primary
121 Seaport Blvd
Boston, Massachusetts, US
Employees at Alexion Pharmaceuticals, Inc.
-
Tom Civitenga
Regional Account Manager at Alexion Pharmaceuticals, Inc.
-
Chad Trexler
Global Sourcing & Procurement Executive & Change Agent
-
Paul Schmidt
Biotech Executive Creating Value with Digital Transformation | Commercial Finance Leader: Pre-Clinical to Revenue Stage – 20 Commercial Products…
-
Seng H. Cheng
Senior Vice President, Research and Product Development at Alexion, AstraZeneca RareDisease
Updates
-
Resuming roles in July, the new European Parliament and Commission will have a generational opportunity this year to overcome health inequities for people living with rare diseases, shaping policies that could address the urgent need for faster diagnosis and increased treatment options. Soraya Bekkali, MD, our SVP for EUCAN and International Business reflects on the opportunities and risks of this historic period in the region: http://spr.ly/604195Zil
-
-
Generalised #MyastheniaGravis (gMG) can be challenging to diagnose because its symptoms often mimic other conditions. Continued research and awareness are critical to help patients receive an earlier diagnosis. #MGAwarenessMonth
-
This week, our Alexion Canada team came together with the Spread The Joy Foundation to pack ‘joy boxes’ full of games, activities and crafts. We were honoured and proud to pack 1,000 boxes that will be sent to 21 hospitals across the country to entertain, educate and spark joy in children who are spending time there. Huge thanks to our enthusiastic Canadian colleagues for their time and engagement and to Spread the Joy for doing such incredibly impactful work for children across North America. Shalini Melwani-Samtani Christina Archer Karen Heim Wendy Erler
-
-
This past week was a memorable one for us at Alexion. We welcomed AstraZeneca CEO Pascal Soriot and his Senior Executive Team (SET) to our Boston headquarters for a full itinerary of events and activities. From attending the R&D Science Day where they received exciting updates from across our therapy area teams, to hosting an energising SET Town Hall during which Pascal shared his perspectives on the business and the future of AZ, to visiting a local nonprofit that provides free temporary housing for patients with medical conditions – this week was filled with lively energy, in-person interaction and meaningful connection. And to top it all off, the week concluded with our new 100 Binney Street site dedicated to Genomic Medicine and an exclusive hard-hat tour of 290 Binney St, a future AZ location, both located in Kendall Square. We’re incredibly proud of the tremendous work taking place across the organisation to drive innovation across the Boston life sciences ecosystem and it reinforces the critical role Boston will play in the future of AZ. Check out a recap of this week’s events below.
-
-
“It takes a village to bring an AI to real world.” Learn about the AI Diagnostic work Chathuri Daluwatte, PhD leads at Alexion.